ストックスクリーナーアプリを入手
0.7715
0.54%
-0.0042
アフターアワーズ：
.78
0.0085
+1.10%
前日終値:
$0.7757
開ける：
$0.7753
24時間の取引高:
121.95K
Relative Volume:
0.26
時価総額：
$63.81M
収益：
$38.70M
当期純損益:
$-117.88M
株価収益率:
-0.4538
EPS:
-1.7
ネットキャッシュフロー:
$-92.84M
1週間 パフォーマンス:
+1.58%
1か月 パフォーマンス:
+17.25%
6か月 パフォーマンス:
-16.31%
1年 パフォーマンス:
-48.91%
1日の値動き範囲:
$0.7551
$0.78
1週間の範囲:
$0.722
$0.8197
52週間の値動き範囲:
$0.4471
$1.70
Adicet Bio Inc Stock (ACET) Company Profile
ACET を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.7715 | 64.16M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-30 | 再開されました | Guggenheim | Buy |
| 2024-09-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-06-27 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-03-31 | 開始されました | SMBC Nikko | Outperform |
| 2022-03-08 | 開始されました | Truist | Buy |
| 2022-03-04 | 開始されました | Jefferies | Buy |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-14 | 開始されました | Canaccord Genuity | Buy |
| 2021-04-08 | 開始されました | Guggenheim | Buy |
| 2020-11-04 | 開始されました | B. Riley Securities | Buy |
| 2020-10-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-16 | 開始されました | Wedbush | Outperform |
すべてを表示
Adicet Bio Inc (ACET) 最新ニュース
Adicet Bio’s (ACET) “Buy” Rating Reiterated at HC Wainwright - Defense World
Q2 Earnings Estimate for Adicet Bio Issued By HC Wainwright - Defense World
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
Does Adicet Bio Inc. stock pay reliable dividendsOutperformance with explosive growth - jammulinksnews.com
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001 - Yahoo Finance
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - BioSpace
What drives Adicet Bio Inc. stock priceConsistently profitable trades - Autocar Professional
Is Adicet Bio Inc. a good long term investmentDynamic growth stocks - Autocar Professional
Adicet Bio doses first systemic sclerosis patient in ADI-001 trial By Investing.com - Investing.com South Africa
Adicet Bio doses first systemic sclerosis patient in ADI-001 trial - Investing.com Australia
Adicet Bio Announces 30% Workforce Reduction Strategy - TipRanks
Adicet Bio stock rating initiated at Buy by H.C. Wainwright - Investing.com Australia
What analysts say about Adicet Bio Inc. stockPhenomenal capital appreciation - jammulinksnews.com
Adicet Bio Inc. Stock Analysis and ForecastOutstanding risk-reward balance - jammulinksnews.com
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Esophageal Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Miltenyi Biomedicine, Adicet Bio, Velosbio, Novartis Pharmaceuticals, Sanofi, - MenaFN
What makes Adicet Bio Inc. stock price move sharplyMarket Ready Callouts - Newser
How Adicet Bio Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Why Adicet Bio Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - Newser
Diffuse Large B-Cell Lymphoma Clinical Trails, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, And Pipeline Analysis Miltenyi Biomedicine, Adicet Bio, Velosbio, Novartis Pharmaceu - MenaFN
Adicet Bio, Inc. (NASDAQ:ACET) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Adicet Bio Elects Directors and Approves Key Proposals - TipRanks
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Squarepoint Ops LLC Purchases New Shares in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio To Present At Jefferies Global Healthcare Conference; Webcast At 4:20 PM ET - Nasdaq
Northern Trust Corp Acquires 28,153 Shares of Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
ACETAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Revista ADVFN
Millennium Management LLC Lowers Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference - Business Wire
Adicet Bio’s SWOT analysis: gamma-delta T cell therapy stock faces pivotal year - Investing.com
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Adicet Bio Inc (ACET) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):